Related Experiment Video
Updated: Apr 1, 2026
10:29
Simulating Pancreatic Neuroplasticity: In Vitro Dual-neuron Plasticity Assay
Published on: April 14, 2014
10.3K
Microarray based analysis of gene expression patterns in pancreatic neuroendocrine tumors
1Department of Hepatobiliary Surgery, the First Affiliated Hospital of Chinese PLA General Hospital, Beijing, China. caishouwangcsw@163.com.
European Review for Medical and Pharmacological Sciences
|October 7, 2015
Summary
Pancreatic neuroendocrine tumors (PanNETs) involve type 2 diabetes pathways. Key genes like SNAP25, SST, and ISG15 show potential as therapeutic targets for PanNETs.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Pancreatic neuroendocrine tumors (PanNETs) exhibit diverse biological behaviors.
- Understanding the molecular underpinnings of PanNETs is crucial for targeted therapies.
Purpose of the Study:
- Identify differentially expressed genes (DEGs) in PanNETs.
- Characterize significant molecular pathways associated with PanNET development.
- Discover potential therapeutic targets for PanNETs.
Main Methods:
- Analyzed gene expression data from 6 PanNETs and 5 non-neoplastic samples (GSE43795).
- Utilized Limma package for DEG identification.
- Performed Gene Ontology (GO) and KEGG pathway enrichment analyses.
- Constructed a protein-protein interaction (PPI) network to identify hub proteins.
Main Results:
- Identified 821 DEGs (421 down-regulated, 400 up-regulated).
- Up-regulated DEGs linked to type 2 diabetes mellitus and Ca2+ signaling pathways.
- Down-regulated DEGs associated with pancreatic secretion and metabolic pathways.
- Identified Interferon-stimulated gene protein 15 (ISG15), somatostatin (SST), and synaptosomal-associated protein 25 kDa (SNAP25) as hub proteins.
Conclusions:
- Genes in the type 2 diabetes mellitus pathway may be critical in PanNET development.
- SNAP25, SST, and ISG15 represent potential therapeutic targets for PanNET treatment.
